| Literature DB >> 36057692 |
Bruce Budowle1, Jianye Ge2,3, Antti Sajantila4,5.
Abstract
Laboratories and their criminal justice systems are confronted with challenges for implementing new technologies, practices, and policies even when there appears to be demonstrative benefits to operational performance. Impacting decisions are the often higher costs associated with, for example, new technologies, limited current budgets, and making hard decisions on what to sacrifice to take on the seemingly better approach. A prospective cost-benefit analysis (CBA) could help an agency better formulate its strategies and plans and more importantly delineate how a relatively small increase to take on, for example, a new technology can have large impact on the system (e.g., the agency, other agencies, victims and families, and taxpayers). To demonstrate the process and potential value a CBA was performed on the use of an alternate and more expensive swab with reported better DNA yield and being certified human DNA free (i.e., nylon 4N6FLOQSwabs®), versus the traditional less costly swab (i.e., cotton swab). Assumptions are described, potential underestimates and overestimates noted, different values applied (for low and modest to high), and potential benefits (monetary and qualitative) presented. The overall outcome is that the cost of using the more expensive technology pales compared with the potential tangible and intangible benefits. This approach could be a guide for laboratories (and associated criminal justice systems) worldwide to support increased funding, although the costs and benefits may vary locally and for different technologies, practices, and policies. With well-developed CBAs, goals of providing the best services to support the criminal justice system and society can be attained.Entities:
Keywords: Cost–benefit analysis; Cotton swab; Database; Forensic genomics; Nylon 4N6FLOQSwabs®; Rape; Sexual assault; Tangible and intangible benefits
Mesh:
Substances:
Year: 2022 PMID: 36057692 PMCID: PMC9576645 DOI: 10.1007/s00414-022-02884-0
Source DB: PubMed Journal: Int J Legal Med ISSN: 0937-9827 Impact factor: 2.791
Steps and general considerations associated with performing a cost–benefit analysis#
| Steps | Process | Considerations |
|---|---|---|
| 1 | Identify and assess the potential impacts of the investment | Is the program feasible? Does it accomplish the desired goal within the lab? Does it impact other sectors? Are there similar initiatives that have been successful? |
| 2 | Measure the costs of the investment | What are the costs to carry out the program within the laboratory? |
| 3 | Measure the costs and benefits of the investment’s impacts | What is the monetary value of the investment’s impacts? Who benefits from the program? Who bears the costs within the laboratory and other impacted sectors? What is the magnitude of the effect for each relevant sector? |
| 4 | Compare costs and benefits | Do the benefits justify the costs (short and long term)? Does the investment in the laboratory operation deliver higher or lower returns than the current system or alternate approaches (if available)? |
| 5 | Test the reliability of the results | Are the assumptions made to predict the expected costs and benefits justified? If assumptions are varied what is the impact? Would different information change the predictions substantially, modestly, or not at all? |
| 6 | Report the results | What are the ways to tabulate the findings and manner to best present the findings and conclusions? |
#Process and considerations derived and modified from Henrichson and Rinaldi [10]
Costs for swabs associated with casework requests#
| Swab type | Cost for all casework requests* | Cost for all sexual assault casework requests** |
|---|---|---|
| Rayon | $149,850 | $20,250 |
| Cotton | $249,750 | $33,750 |
| Nylon*** | $2,047,950 | $276,750 |
#Casework request numbers derived from Bureau of Justice Statics [23]
*Costs are based on 5 swabs for each of 333,000 cases, assumes that only one swab type is used by all evidence collectors.
**Costs are based on 5 swabs for each of 45,000 cases (which are a subset of the 333,000 cases), assumes that only one swab type is used by all evidence collectors.
***The nylon swab in a tube price of $1.23 per swab was used for calculations.
Number of additional profiles uploaded from sexual assault cases due to increased DNA yield
| % increase of profile uploads | Number increase of profile uploads* |
|---|---|
| 10 | 1530 |
| 20 | 3060 |
| 30 | 4590 |
*Calculated as 45,000 cases × 10, 20, or 30% increase × 0.34.
Tangible costs# associated with sexual assault cases and increased profiles uploaded to a database
| Number of sexual assault profiles uploaded | Medical cost ($1835) | Public service## cost ($25) | Adjudication and sanctioning cost## ($852) | Total cost## |
|---|---|---|---|---|
| 1530 | $2,807,550 | $38,250 | $1,303,560 | $4,149,360 |
| 3060 | $5,616,100 | $76,500 | $2,607,120 | $8,299,720 |
| 4590 | $8,422,650 | $114,750 | $3,910,680 | $12,448,080 |
#Cost per category derived from Miller et al. [28]
##Assumes that all cases are subject to these categories, which is unlikely. However, the data in Miller et al. [28] factored the monetary value overall cases.
Costs# associated with serial rapes that may be captured with increase upload of profiles to a database
| Benefits | 77 victims## | 688 victims### |
|---|---|---|
| Medical | $141,295 | $1,262,480 |
| Public service | $1925 | $17,200 |
| Adjudication | $65,604 | $596,176 |
| Total tangible*** | $208,824 | $1,865,856 |
| Intangible | $16,517,886 | $147,588,384 |
| Total tangible and intangible | $16,726,710 | $149,454,240 |
#Cost per category derived from Miller et al. [28]. Note that a sub-amount of total tangible costs only considering those categories listed in this table.
##Calculated as 0.05 × low end estimate (10%) of increased uploads. Note that 77 victims are 5% of the 1530 uploaded profiles in Table 3
###Calculated as 0.15 × high end estimate (30%) of increased uploads. Note that 688 victims are 15% of 4590 profiles uploaded from Table 3
***Total tangible is the sum of medical, public service, and adjudication costs.